The use of multiattribute decision models in evaluating triptan treatment options in migraine

Michel D. Ferrari, Peter J. Goadsby, Richard B. Lipton, David W. Dodick, F. Michael Cutrer, Douglas McCrory, Paul Williams

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The physician treating patients with migraine is now able to choose from among seven triptans-almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan. These differ, to greater or lesser degrees, on a range of clinical attributes important for treatment selection. Objective: To outline the basic principles of Multiattribute Decision Making (MADM) and describe how one such method-TOPSIS (Technique for Order Preference by Similarity to the Ideal Solution)-can be applied to evaluate the currently available triptans. Methods: In an example application, summary data from a recent meta-analysis of 53 published and unpublished placebo-controlled trials of the oral triptans were combined in TOPSIS models with computer-generated attribute importance weights representing the entire range of possible values, That is, the relative performance of the triptans was explored across all logically possible combinations of relative importance of the treatment attributes available from the meta-analysis, and uncertainty was assessed based on the confidence intervals from the meta-analysis. Results: When compared across the entire range of values for relative attribute importance, almotriptan, eletriptan and rizatriptan were more similar to a hypothetical ideal triptan and were more likely to appear in the top three closest to the hypothetical ideal, than were naratriptan, sumatriptan, and zolmitriptan. Conclusions: Using the TOPSIS model, almotriptan, eletriptan and rizatriptan were more likely to appear in the top three closest to the hypothetical ideal triptan.

Original languageEnglish (US)
Pages (from-to)1026-1032
Number of pages7
JournalJournal of Neurology
Volume252
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Tryptamines
Migraine Disorders
zolmitriptan
Sumatriptan
Meta-Analysis
Therapeutics
Computer Simulation
Uncertainty
Decision Making
Placebos
Confidence Intervals
Physicians
Weights and Measures
rizatriptan
almotriptan
eletriptan

Keywords

  • Decision model
  • Migraine
  • Triptans

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Ferrari, M. D., Goadsby, P. J., Lipton, R. B., Dodick, D. W., Cutrer, F. M., McCrory, D., & Williams, P. (2005). The use of multiattribute decision models in evaluating triptan treatment options in migraine. Journal of Neurology, 252(9), 1026-1032. https://doi.org/10.1007/s00415-005-0769-0

The use of multiattribute decision models in evaluating triptan treatment options in migraine. / Ferrari, Michel D.; Goadsby, Peter J.; Lipton, Richard B.; Dodick, David W.; Cutrer, F. Michael; McCrory, Douglas; Williams, Paul.

In: Journal of Neurology, Vol. 252, No. 9, 09.2005, p. 1026-1032.

Research output: Contribution to journalArticle

Ferrari, MD, Goadsby, PJ, Lipton, RB, Dodick, DW, Cutrer, FM, McCrory, D & Williams, P 2005, 'The use of multiattribute decision models in evaluating triptan treatment options in migraine', Journal of Neurology, vol. 252, no. 9, pp. 1026-1032. https://doi.org/10.1007/s00415-005-0769-0
Ferrari, Michel D. ; Goadsby, Peter J. ; Lipton, Richard B. ; Dodick, David W. ; Cutrer, F. Michael ; McCrory, Douglas ; Williams, Paul. / The use of multiattribute decision models in evaluating triptan treatment options in migraine. In: Journal of Neurology. 2005 ; Vol. 252, No. 9. pp. 1026-1032.
@article{c9b51cbe1a054ea6ac2b684226f21df5,
title = "The use of multiattribute decision models in evaluating triptan treatment options in migraine",
abstract = "Background: The physician treating patients with migraine is now able to choose from among seven triptans-almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan. These differ, to greater or lesser degrees, on a range of clinical attributes important for treatment selection. Objective: To outline the basic principles of Multiattribute Decision Making (MADM) and describe how one such method-TOPSIS (Technique for Order Preference by Similarity to the Ideal Solution)-can be applied to evaluate the currently available triptans. Methods: In an example application, summary data from a recent meta-analysis of 53 published and unpublished placebo-controlled trials of the oral triptans were combined in TOPSIS models with computer-generated attribute importance weights representing the entire range of possible values, That is, the relative performance of the triptans was explored across all logically possible combinations of relative importance of the treatment attributes available from the meta-analysis, and uncertainty was assessed based on the confidence intervals from the meta-analysis. Results: When compared across the entire range of values for relative attribute importance, almotriptan, eletriptan and rizatriptan were more similar to a hypothetical ideal triptan and were more likely to appear in the top three closest to the hypothetical ideal, than were naratriptan, sumatriptan, and zolmitriptan. Conclusions: Using the TOPSIS model, almotriptan, eletriptan and rizatriptan were more likely to appear in the top three closest to the hypothetical ideal triptan.",
keywords = "Decision model, Migraine, Triptans",
author = "Ferrari, {Michel D.} and Goadsby, {Peter J.} and Lipton, {Richard B.} and Dodick, {David W.} and Cutrer, {F. Michael} and Douglas McCrory and Paul Williams",
year = "2005",
month = "9",
doi = "10.1007/s00415-005-0769-0",
language = "English (US)",
volume = "252",
pages = "1026--1032",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "9",

}

TY - JOUR

T1 - The use of multiattribute decision models in evaluating triptan treatment options in migraine

AU - Ferrari, Michel D.

AU - Goadsby, Peter J.

AU - Lipton, Richard B.

AU - Dodick, David W.

AU - Cutrer, F. Michael

AU - McCrory, Douglas

AU - Williams, Paul

PY - 2005/9

Y1 - 2005/9

N2 - Background: The physician treating patients with migraine is now able to choose from among seven triptans-almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan. These differ, to greater or lesser degrees, on a range of clinical attributes important for treatment selection. Objective: To outline the basic principles of Multiattribute Decision Making (MADM) and describe how one such method-TOPSIS (Technique for Order Preference by Similarity to the Ideal Solution)-can be applied to evaluate the currently available triptans. Methods: In an example application, summary data from a recent meta-analysis of 53 published and unpublished placebo-controlled trials of the oral triptans were combined in TOPSIS models with computer-generated attribute importance weights representing the entire range of possible values, That is, the relative performance of the triptans was explored across all logically possible combinations of relative importance of the treatment attributes available from the meta-analysis, and uncertainty was assessed based on the confidence intervals from the meta-analysis. Results: When compared across the entire range of values for relative attribute importance, almotriptan, eletriptan and rizatriptan were more similar to a hypothetical ideal triptan and were more likely to appear in the top three closest to the hypothetical ideal, than were naratriptan, sumatriptan, and zolmitriptan. Conclusions: Using the TOPSIS model, almotriptan, eletriptan and rizatriptan were more likely to appear in the top three closest to the hypothetical ideal triptan.

AB - Background: The physician treating patients with migraine is now able to choose from among seven triptans-almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan. These differ, to greater or lesser degrees, on a range of clinical attributes important for treatment selection. Objective: To outline the basic principles of Multiattribute Decision Making (MADM) and describe how one such method-TOPSIS (Technique for Order Preference by Similarity to the Ideal Solution)-can be applied to evaluate the currently available triptans. Methods: In an example application, summary data from a recent meta-analysis of 53 published and unpublished placebo-controlled trials of the oral triptans were combined in TOPSIS models with computer-generated attribute importance weights representing the entire range of possible values, That is, the relative performance of the triptans was explored across all logically possible combinations of relative importance of the treatment attributes available from the meta-analysis, and uncertainty was assessed based on the confidence intervals from the meta-analysis. Results: When compared across the entire range of values for relative attribute importance, almotriptan, eletriptan and rizatriptan were more similar to a hypothetical ideal triptan and were more likely to appear in the top three closest to the hypothetical ideal, than were naratriptan, sumatriptan, and zolmitriptan. Conclusions: Using the TOPSIS model, almotriptan, eletriptan and rizatriptan were more likely to appear in the top three closest to the hypothetical ideal triptan.

KW - Decision model

KW - Migraine

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=25144438988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144438988&partnerID=8YFLogxK

U2 - 10.1007/s00415-005-0769-0

DO - 10.1007/s00415-005-0769-0

M3 - Article

VL - 252

SP - 1026

EP - 1032

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 9

ER -